We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Human Metabolome Technologies, Inc., Expands to U.S.

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

“Cambridge provides the perfect combination of academic and industrial arenas, especially associated with the field of life sciences, food engineering and environmental studies,” said Tsutomu (Tom) Hoshiba, President, HMT America. “HMT provides cutting-edge solutions to life scientists, medical doctors and pharmacologists via our state-of-the-art metabolomics technology based on capillary electrophoresis mass spectrometry (CE-MS), and we believe that Cambridge is the place to be for networking with businesses that will make the most of our solutions.”

The office location was based largely on accessibility for globally competitive pharmaceutical companies and research institutions to HMT’s most important metabolome analysis services, CARCINOSCOPE, which was specifically designed for cancer research, and BASIC SCAN for more global, general-purpose metabolomics research, including biomarker discovery and companion diagnostics.

“Thanks to our growth strategy of investing in education, innovation and infrastructure, Massachusetts continues to lead the world in life sciences,” said Governor Deval Patrick. “We welcome HMT to Massachusetts and look forward to working with them to create jobs and opportunities in the Commonwealth.”

“On behalf of the Center, I would like to extend our warmest congratulations to the team at HMT as they open their first U.S. office here in Massachusetts,” said Susan Windham-Bannister, Ph.D., President & CEO of the Massachusetts Life Sciences Center, the agency charged with implementing Governor Patrick’s 10-year, $1 billion Life Sciences Initiative. “Massachusetts is a global leader in cancer drug development, and HMT will be an important new addition to our oncology community. We are very excited that HMT has chosen to build its metabolomics technology business here.”